Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice

Journal of Virology

Volumn 88, Issue 17, 2014, Pages 9693-9703

  Kim, Eun Hye ^a   Park, Hae Jung ^a   Han, Gye Yeong ^a   Song, Man Ki ^a   Pereboev, Alexander ^b   Hong, Jeong S ^c   Chang, Jun ^d   Byun, Young Ho ^e   Seong, Baik Lin ^e   Nguyen, Huan H ^a  

^a International Vaccine Institute   (South Korea)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Ewha Womans University   (South Korea)

^e Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; HEMAGGLUTININ, AVIAN INFLUENZA A VIRUS; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; M1 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ADENOVIRIDAE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CROSS PROTECTION; DISEASE MODEL; FEMALE; GENE VECTOR; GENETICS; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PROCEDURES; VACCINATION; VIROLOGY;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA VACCINES; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VACCINES, SYNTHETIC; VIRAL MATRIX PROTEINS;

EID: 84921983245     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00823-14     Document Type: Article

References (59)

1. Aballéa S, Martin CJM, Wutzler P, Carrat F, Gasparini R, Toniolo-Neto J, Drummond M, Weinstein M. 2007. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health 10:98-116. http://dx.doi.org/10.1111/j.1524-4733.2006.00157.x.
2. Clements ML, Betts RF, Tierney EL, Murphy BR. 1986. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 24:157-160.
3. Couch RB. 1975. Assessment of immunity to influenza using artificial challenge of normal volunteers with influenza virus. Dev. Biol. Stand. 28:295-306.
4. Hobson D, Curry RL, Beare AS, Ward-Gardner A. 1972. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.) 70:767-777. http://dx.doi.org/10.1017/S0022172400022610.
5. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW. 2004. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22:2993-3003. http://dx.doi.org/10.1016/j.vaccine.2004.02.021.
6. Liu W, Zou P, Chen Y-H. 2004. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol. Lett. 93:131-136. http://dx.doi.org/10.1016/j.imlet.2004.03.003.
7. Mozdzanowska K, Maiese K, Furchner M, Gerhard W. 1999. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 254:138-146. http://dx.doi.org/10.1006/viro.1998.9534.
8. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. 1999. A universal influenza A vaccine based on the extracellular domain of theM2protein. Nat. Med. 5:1157-1163. http://dx.doi.org/10.1038/13484.
9. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. 1990. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J. Virol. 64:1375-1377.
10. Frace AM, Klimov AI, Rowe T, Black RA, Katz JM. 1999. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 17:2237-2244. http://dx.doi.org/10.1016/S0264-410X(99)00005-5.
11. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L, Jr, Gerhard W. 2003. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21:2616-2626. http://dx.doi.org/10.1016/S0264-410X(03)00040-9.
12. Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, Hamajima K, Yang J, Ishii N, Nakazawa M, Okuda K, Ohnari K, Nakajima K, Xin KQ. 2001. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenzaMgene. Vaccine 19: 3681-3691. http://dx.doi.org/10.1016/S0264-410X(01)00078-0.
13. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. 1995. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressedM2protein. Vaccine 13:1399-1402. http://dx.doi.org/10.1016/0264-410X(95)92777-Y.
14. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5:1157-1163. http://dx.doi.org/10.1038/13484.
15. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu T-M, Joyce J, Przysiecki CT, Keller PM. 2004. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22:2993-3003. http://dx.doi.org/10.1016/j.vaccine.2004.02.021.
16. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL. 2007. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg. Infect. Dis. 13:426-435. http://dx.doi.org/10.3201/eid1303.061125.
17. Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, Cheon IS, Joo DH, Cho CH, Song MS, Seo SU, Byun YH, Park HJ, Poo H, Seong BL, Kim JO, Nguyen HH, Stadler K, Kim DW, Hong KJ, Czerkinsky C, Song MK. 2011. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS One 6:e27953. http://dx.doi.org/10.1371/journal.pone.0027953.
18. Song JM, Wang BZ, Park KM, Van Rooijen N, Quan FS, Kim MC, Jin HT, Pekosz A, Compans RW, Kang SM. 2011. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 6:e14538. http://dx.doi.org/10.1371/journal.pone.0014538.
19. Krystal M, Elliott RM, Benz EW, Jr, Young JF, Palese P. 1982. Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes. P. Natl. Acad. Sci. U. S. A. 79:4800-4804. http://dx.doi.org/10.1073/pnas.79.15.4800.
20. Okuno Y, Isegawa Y, Sasao F, Ueda S. 1993. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67:2552-2558.
21. Bommakanti G, Citron MP, Hepler RW, Callahan C, Heidecker GJ, Najar TA, Lu X, Joyce JG, Shiver JW, Casimiro DR, ter Meulen J, Liang X, Varadarajan R. 2010. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. P Natl. Acad. Sci. U. S. A. 107:13701-13706. http://dx.doi.org/10.1073/pnas.1007465107.
22. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, Garcia-Sastre A, Palese P. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1:e00018-10. http://dx.doi.org/10.1128/mBio.00018-10.
23. Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR, Banach D, Wrammert J, Belshe RB, Garcia-Sastre A, Palese P. 2012. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. P Natl. Acad. Sci. U. S. A. 109:2573-2578. http://dx.doi.org/10.1073/pnas.1200039109.
24. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, Andersen H, Rao S, Tumpey TM, Yang ZY, Nabel GJ. 2010. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329:1060-1064. http://dx.doi.org/10.1126/science.1192517.
25. Krammer F, Pica N, Hai R, Margine I, Palese P. 2013. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87:6542-6550. http://dx.doi.org/10.1128/JVI.00641-13.
26. Schepp-Berglind J, Luo M, Wang D, Wicker JA, Raja NU, Hoel BD, Holman DH, Barrett AD, Dong JY. 2007. Complex adenovirusmediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses. Clin. Vaccine Immunol. 14:1117-1126. http://dx.doi.org/10.1128/CVI.00070-07.
27. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424:681-684. http://dx.doi.org/10.1038/nature01876.
28. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605-609. http://dx.doi.org/10.1038/35046108.
29. Tatsis N, Ertl HC. 2004. Adenoviruses as vaccine vectors. Mol. Ther. 10:616-629. http://dx.doi.org/10.1016/j.ymthe.2004.07.013.
30. Timofeev AV, Ozherelkov SV, Pronin AV, Deeva AV, Karganova GG, Elbert LB, Stephenson JR. 1998. Immunological basis for protection in a murine model of tick-borne encephalitis by a recombinant adenovirus carrying the gene encoding the NS1 nonstructural protein. J. Gen. Virol. 79(Pt 4):689-695.
31. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, Nabel GJ. 2005. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23:5404-5410. http://dx.doi.org/10.1016/j.vaccine.2005.04.047.
32. Kim SH, Kim JY, Choi Y, Nguyen HH, Song MK, Chang J. 2013. Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection. PLoS One 8:e75460. http://dx.doi.org/10.1371/journal.pone.0075460.
33. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, Matsuoka Y, Robbins PD, Swayne DE, Donis RO, Katz JM, Barratt-Boyes SM, Gambotto A. 2006. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol. 80:1959-1964. http://dx.doi.org/10.1128/JVI.80.4.1959-1964.2006.
34. Hoelscher MA, Singh N, Garg S, Jayashankar L, Veguilla V, Pandey A, Matsuoka Y, Katz JM, Donis R, Mittal SK, Sambhara S. 2008. A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J. Infect. Dis. 197:1185-1188. http://dx.doi.org/10.1086/529522.
35. Rao SS, Kong WP, Wei CJ, Van Hoeven N, Gorres JP, Nason M, Andersen H, Tumpey TM, Nabel GJ. 2010. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS One 5:e9812. http://dx.doi.org/10.1371/journal.pone.0009812.
36. Wang YQ, Qi LW, Aa J, Wang GJ, Gao W, Cheng SJ, Wang ZZ, Xiao W, Li P. 2012. Comprehensive chemical profiling of guizhi fuling capsule by the combined use of gas chromatography-mass spectrometry with a deconvolution software and rapid-resolution liquid chromatography quadrupole time-of-flight tandem mass spectrometry. Biomed. Chromatogr. 26:1286-1296. http://dx.doi.org/10.1002/bmc.2695.
37. Shmarov MM, Sedova ES, Verkhovskaya LV, Rudneva IA, Bogacheva EA, Barykova YA, Shcherbinin DN, Lysenko AA, Tutykhina IL, Logunov DY, Smirnov YA, Naroditsky BS, Gintsburg AL. 2010. Induction of a protective heterosubtypic immune response against the influenza virus by using recombinant adenoviral vectors expressing hemagglutinin of the influenza H5 virus. Acta Naturae 2:111-118.
38. Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, Marks D, Elmets CA, Tang DC. 2005. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23:1029-1036. http://dx.doi.org/10.1016/j.vaccine.2004.07.043.
39. Brandtzaeg P. 2003. Role of mucosal immunity in influenza. Dev. Biol. (Basel) 115:39-48.
40. Gallichan WS, Rosenthal KL. 1996. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J. Exp. Med. 184:1879-1890. http://dx.doi.org/10.1084/jem.184.5.1879.
41. Nguyen HH, Moldoveanu Z, Novak MJ, van Ginkel FW, Ban E, Kiyono H, McGhee JR, Mestecky J. 1999. Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8+ cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology 254:50-60. http://dx.doi.org/10.1006/viro.1998.9521.
42. Nguyen HH, Tumpey TM, Park HJ, Byun YH, Tran LD, Nguyen VD, Kilgore PE, Czerkinsky C, Katz JM, Seong BL, Song JM, Kim YB, Do HT, Nguyen T, Nguyen CV. 2010. Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice. PLoS One 5:e10152. http://dx.doi.org/10.1371/journal.pone.0010152.
43. Nguyen HH, van Ginkel FW, Vu HL, McGhee JR, Mestecky J. 2001. Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J. Infect. Dis. 183:368-376. http://dx.doi.org/10.1086/318084.
44. Hai R, Krammer F, Tan GS, Pica N, Eggink D, Maamary J, Margine I, Albrecht RA, Palese P. 2012. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J. Virol. 86:5774-5781. http://dx.doi.org/10.1128/JVI.00137-12.
45. Maines TR, Lu XH, Erb SM, Edwards L, Guarner J, Greer PW, Nguyen DC, Szretter KJ, Chen LM, Thawatsupha P, Chittaganpitch M, Waicharoen S, Nguyen DT, Nguyen T, Nguyen HH, Kim JH, Hoang LT, Kang C, Phuong LS, Lim W, Zaki S, Donis RO, Cox NJ, Katz JM, Tumpey TM. 2005. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J. Virol. 79:11788-11800. http://dx.doi.org/10.1128/JVI.79.18.11788-11800.2005.
46. Park HJ, Ferko B, Byun YH, Song JH, Han GY, Roethl E, Egorov A, Muster T, Seong B, Kweon MN, Song M, Czerkinsky C, Nguyen HH. 2012. Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice. PLoS One 7:e39921. http://dx.doi.org/10.1371/journal.pone.0039921.
47. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Brakenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmit J. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333:843-850. http://dx.doi.org/10.1126/science.1204839.
48. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL. 2009. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27:6512-6521. http://dx.doi.org/10.1016/j.vaccine.2009.08.053.
49. Soboleski MR, Gabbard JD, Price GE, Misplon JA, Lo CY, Perez DR, Ye J, Tompkins SM, Epstein SL. 2011. Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS One 6:e21937. http://dx.doi.org/10.1371/journal.pone.0021937.
50. Braucher DR, Henningson JN, Loving CL, Vincent AL, Kim E, Steitz J, Gambotto AA, Kehrli ME, Jr. 2012. Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs. Clin. Vaccine Immunol. 19:1722-1729. http://dx.doi.org/10.1128/CVI.00315-12.
51. Wei CJ, Yassine HM, McTamney PM, Gall JG, Whittle JR, Boyington JC, Nabel GJ. 2012. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci. Transl. Med. 4:147ra114. http://dx.doi.org/10.1126/scitranslmed.3004273.
52. Rogers GN, Paulson JC, Daniels RS, Skehel JJ, Wilson IA, Wiley DC. 1983. Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity. Nature 304:76-78. http://dx.doi.org/10.1038/304076a0.
53. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, Van Rooijen N, Verbeek S, Fiers W, Saelens X. 2011. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186: 1022-1031. http://dx.doi.org/10.4049/jimmunol.0902147.
54. Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X. 2009. M2e-based universal influenza A vaccine. Vaccine 27:6280-6283. http://dx.doi.org/10.1016/j.vaccine.2009.07.007.
55. Hillaire ML, van Trierum SE, Kreijtz JH, Bodewes R, Geelhoed-Mieras MM, Nieuwkoop NJ, Fouchier RA, Kuiken T, Osterhaus AD, Rimmelzwaan GF. 2011. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T cells. J. Gen. Virol. 92:2339-2349. http://dx.doi.org/10.1099/vir.0.033076-0.
56. Weinfurter JT, Brunner K, Capuano SV, III, Li C, Broman KW, Kawaoka Y, Friedrich TC. 2011. Cross-reactiveTcells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog. 7:e1002381. http://dx.doi.org/10.1371/journal.ppat.1002381.
57. Epstein SL, Lo CY, Misplon JA, Lawson CM, Hendrickson BA, Max EE, Subbarao K. 1997. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, β2-microglobulin-deficient, and J-chain-deficient mice. J. Immunol. 158: 1222-1230.
58. Krammer F, Palese P. 2013. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. 3:521-530. http://dx.doi.org/10.1016/j.coviro.2013.07.007.
59. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, Feldmann H, Kobinger GP. 2008. Nasal delivery of an adenovirus-based vaccine bypasses preexisting immunity to the vaccine carrier and improves the immune response in mice. PLoS One 3:e3548. http://dx.doi.org/10.1371/journal.pone.0003548.